Sun Pharmaceutical Industries, India’s largest drugmaker, has received approval from the South African Health Products Regulatory Authority (SAHPRA) to market a generic version of semaglutide injection. The approval marks a…
The landmark India-UK Comprehensive Economic Trade Agreement (CETA) came into effect on July 15, 2026, marking a new chapter for Indian pharmaceutical exports to Britain. The Pharmaceutical Export Promotion Council…
Indian pharmaceutical companies are executing a strategic pivot in 2026 — doubling down on specialty drugs and biosimilars through record-breaking M&A and US investment, while maintaining their core generics business…
The Indian pharmaceutical sector enters the second half of 2026 with significant momentum as three major developments converge: the India-UK Comprehensive Economic Trade Agreement (CETA) taking effect on July 15,…